Navigation Links
A New Therapy to Protect Cancer Patients Against Infertility

eatments work, but the medications used have been long-acting and therefore cause shutdown for the whole time the patient is in chemo.

This means that patients get unpleasant side effects related to having low oestrogen levels, such as hot flushes, and can also lead to loss of bone mass.

The side effects associated with the cyclical use of GnRH antagonists were minimal, she said. 19% of patients did not experience any at all, and only 6% reported persistent side effects, none of which were dangerous or serious.

Dr. Stern and her team are currently completing a five year follow up of the pilot study. We are optimistic that this will prove to be an effective way of protecting fertility for women without the problems that have been associated with GnRH agonists in the past, she said.

The medical community needs to acknowledge the importance of future fertility for young people having cancer treatment. Not all patients who are having cancer treatment have the opportunity to talk with a fertility specialist before beginning treatment, and yet there are already several options for protecting the ovaries and even preserving eggs, embryos, or ovarian tissue.

In addition to raising awareness among the medical profession, more support is needed for research in this important area.


'"/>




Page: 1 2

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
(Date:12/2/2008)...tCall/ -- Quest Diagnostics Incorporated (NYSE: ...testing, information and services, announced that ...thcare Conference in New York City today, December...cheduled to begin at 4:00 p.m. Eastern Time. , ...affirm its 2008 guidance for revenue growth of gre...
(Date:12/2/2008)...er with aprotinin, a drug commonly used to control...y, compared with lysine analogues, according to a ...9 to be published in the January 20th issue of C...dvisory panel will meet to decide on aprotinin use...the meeting. , The study, a systematic review o...
(Date:12/2/2008)...rstCall/ - NUCRYST Pharmaceuticals Corp., a develo...t infection and inflammation, announced today that...rity shareholder, The Westaim Corporation ("Westai...areholders to consider a return of capital of US$0...s to a return of capital of approximately US$15 mi...
(Date:12/2/2008)...e Efficacy of Commercially Available Hypomethylati... Eisai Corporation of North Americ...rst clinical trial evaluating the activity of Daco...za(R) (azacitidine) in adult patients with interme...ic syndromes (MDS), a potentially life-threatening...
Breaking Medicine News(10 mins):Health News:Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 3Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3
...pmental Biology, members of Dr. John Herr’s labora...eport the discovery// of a new protein within a sp...contraceptive drugs. “There’s considerable intere...es,” said Herr, who heads UVa’s Center for Researc...
...Medical Center have developed the first gene chip,...diagnosis of at// least five hereditary liver dise...causes of jaundice in children and adults, and pot...nt options. The Cincinnati Children's study resul...
...ad, medical science miracles will be a fact - tech...treatments will stand to// reshape the lives of pe...planning department at Eastern Virginia Medical Sc...sh Medical Journal based on these technologies. &...
...ck pain are effective, a new review of studies has...ological outcomes such as// depression and health-...’ experience of pain. “Because this analysis was...ative than previous reviews, we have the best evid...
Other Medicine News:Health News:Male Contraception: Discovery Stirring Interest Among Scientists, Drug Developers 2Health News:First Gene Chip Discovered by Cincinnati Researchers 2Health News:First Gene Chip Discovered by Cincinnati Researchers 3Health News:Medical Science Miracles – Coming Your Wa 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 3
(Date:11/25/2008)...ss Survival of Patients Receiving Litx versus Stan...ular Carcinoma , , BELLEVUE, Wash., Nov. 25...O) today announced the completion of enrollment in... Therapy(TM) (Litx(TM)) as a treatment for unresec...s hepatoma or primary liver cancer. , , The...
(Date:11/24/2008)...ewswire/ -- Takeda Pharmaceutical Company Limited ...earch & Development Center, Inc., U.S., announ... the U.S. Food and Drug Administration (FDA) recom...eatment of hyperuricemia in patients with gout. Th...ne panel member abstaining. The vote followed pres...
(Date:11/24/2008).../ -- Leaders of Schering-Plough Corporation (NYSE:... the company,s research pipeline, highlighting a r...entities in clinical trials or under regulatory re...search and development is adding strength and brea...mation," said Fred Hassan, chairman and CEO. "Our...
(Date:11/24/2008)... long-term commitment to hepatitis research , ...ll/ -- Schering-Plough Corporation (NYSE: SGP ) ...s lead investigational oral hepatitis C protease i...company believes boceprevir has the potential to b...bitor for treating chronic hepatitis C. The compa...
Breaking Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 1Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 2Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 3Using DNA scientists hunt for the roots of the modern potato 2050 1Using DNA scientists hunt for the roots of the modern potato 2050 2American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 1American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 2Flextronics Announces Third Quarter Results 10427 1Flextronics Announces Third Quarter Results 10427 2Flextronics Announces Third Quarter Results 10427 3Flextronics Announces Third Quarter Results 10427 4Flextronics Announces Third Quarter Results 10427 5Flextronics Announces Third Quarter Results 10427 6Flextronics Announces Third Quarter Results 10427 7Flextronics Announces Third Quarter Results 10427 8Flextronics Announces Third Quarter Results 10427 9Flextronics Announces Third Quarter Results 10427 10Flextronics Announces Third Quarter Results 10427 11Flextronics Announces Third Quarter Results 10427 12Flextronics Announces Third Quarter Results 10427 13Flextronics Announces Third Quarter Results 10427 14Flextronics Announces Third Quarter Results 10427 15Flextronics Announces Third Quarter Results 10427 16Flextronics Announces Third Quarter Results 10427 17Flextronics Announces Third Quarter Results 10427 18Flextronics Announces Third Quarter Results 10427 19
...Calif., June 05, 2007 /PRNewswire/ -- MAP,Pharmace... Phase 2,data from its MAP0004 migraine therapy cl...e Society Meeting at the Hyatt Regency,Chicago in ...was,accepted as a late-breaker, is entitled Rapid ...led Dihydroergotamine Mesylate,via a Novel Inhaler...
...une 05, 2007 /PRNewswire/ -- , Professor Home said...ppointing and,misleading in that they disregarded ...nt to patients and physicians. Most,significantly ...e,of any increase in cardiovascular death or death...T: Professor Philip Home, (44) 778-525-1736 , Ter...
Other Medicine Technology:MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the,American Headache Society Meeting 2
...e BP monitor is designed to automatically measure ...BP along with heart rate. It's a Blood Pressure mo...ergometer and pharmacological stress test environm...ronments., ,Tango excels where other BP monit...
BD Visiswab Cotton Swab
...l, Philips Zymed 1810 Series offers retrospective ... the operator the flexibility to adjust the algori...application beyond the basic 1810 and you have eve...matic style that best meets the challenges of each...
...s STG for PC captures, displays, replays and analy...be effective in evaluating heart illnesses, pneumo...ase.,It provides objective evidence as a complem...time-expanded waveform displays, Phonocardiogra...
Medicine Products: